\n| International Criteria [13]<\/td>\n | 2017<\/td>\n | ~1.3\u20133.0%<\/td>\n | ~4.2\u20136.8%<\/td>\n | Formal normal\/borderline\/abnormal categories; two or more borderline findings required to trigger evaluation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n The 2017 International Criteria define exactly five borderline findings: left axis deviation, right axis deviation, left atrial enlargement, right atrial enlargement, and complete right bundle branch block [13]. Any single one of these in isolation does not warrant evaluation in an asymptomatic athlete without concerning family history; two or more do. Isolated voltage criteria for left or right ventricular hypertrophy are classified as normal, not borderline \u2014 a point frequently misstated.<\/p>\n Two caveats matter. First, the reported false-positive rates derive from expert or specialist-supervised interpretation; rates under non-specialist reading are consistently higher, and the magnitude of that gap has not been established at scale. Second, gains in specificity have not been free: in masters and pediatric cohorts, the International Criteria have missed diagnoses that earlier criteria would have flagged, including dilated cardiomyopathy presenting with isolated left axis deviation.<\/p>\n 6.2 Diagnostic versus screening sensitivity<\/h4>\nAn important distinction is frequently elided. Diagnostic sensitivity<\/strong> is the probability that a person with established, fully expressed disease has an abnormal ECG. Screening sensitivity<\/strong> is the probability that an asymptomatic adolescent with early, incomplete, or concealed expression is correctly identified in a mass-screening setting.<\/p>\nThe second is systematically lower than the first. Adolescent phenotype is often immature \u2014 both hypertrophic and arrhythmogenic cardiomyopathy express progressively \u2014 dynamic conditions are intermittently normal at rest, and field acquisition and interpretation conditions are inferior to those of a referral laboratory. Sensitivity figures quoted from referral cohorts of patients with known disease, commonly cited near 98% for hypertrophic cardiomyopathy, should not be presented as screening performance [18].<\/p>\n The most instructive evidence comes from long-term follow-up of a screened cohort. Among 11,168 adolescent English Football Association players screened with questionnaire, examination, ECG, and echocardiography, conditions associated with sudden death were identified in 0.38%, with ECG abnormal in 86% of those individuals versus 7% for history and 5% for physical examination [19]. Over a mean 10.6 years of follow-up, however, eight athletes died of cardiac causes \u2014 six of whom had screened normal at age 16, at a mean of 6.8 years after screening, most from cardiomyopathies not detectable at the time of testing.<\/p>\n A normal screen is not durable clearance.<\/strong> This is a property of progressive disease, not a failure of the test.<\/p>\n6.3 Secondary evaluation<\/h4>\nAn abnormal primary screen or concerning symptom initiates further testing, selected by the suspected condition rather than applied as a fixed panel.<\/p>\n Transthoracic echocardiography<\/strong> assesses wall thickness, chamber dimensions, systolic and diastolic function, valvular structure, aortic dimensions, and in many cases coronary origins.<\/p>\nCardiac magnetic resonance<\/strong> provides superior tissue characterization. Late gadolinium enhancement identifies fibrosis and scar; T2-weighted imaging and parametric mapping identify edema and active inflammation. It is often decisive in distinguishing physiological hypertrophy from cardiomyopathy, in evaluating the right ventricle for arrhythmogenic cardiomyopathy, and in diagnosing myocarditis. Late gadolinium enhancement confined to right ventricular insertion points is a recognized finding without established adverse prognostic significance.<\/p>\nExercise testing<\/strong> should be sport-specific and designed to provoke symptoms at the intensity actually encountered in competition, rather than terminated at arbitrary heart-rate targets or performed pharmacologically. It is essential in suspected CPVT, in evaluating ventricular ectopy, and in assessing ischemia in anomalous coronary anatomy.<\/p>\nAmbulatory rhythm monitoring<\/strong> characterizes arrhythmia burden and its relationship to activity; extended monitoring is often required given the intermittency of clinically relevant events.<\/p>\nCoronary imaging<\/strong> by CT angiography or magnetic resonance is required to define coronary origin and course when anomalous anatomy is suspected.<\/p>\nGenetic testing<\/strong> confirms diagnosis where the phenotype is established, informs risk stratification in specific conditions \u2014 plakophilin-2 in arrhythmogenic cardiomyopathy, lamin A\/C in dilated cardiomyopathy, genotype in long QT syndrome \u2014 and enables cascade screening of relatives. It performs poorly as a primary diagnostic test in the absence of phenotype or family history, where it principally generates variants of uncertain significance.<\/p>\nNotably, cardiac imaging, exercise testing, and ambulatory monitoring have insufficient evidence to support their use as primary screening tools in asymptomatic individuals [1]. Their role is in secondary evaluation.<\/p>\n 6.4 Emerging technologies<\/h4>\nArtificial intelligence applied to the ECG.<\/strong> Deep learning models trained on large ECG corpora can identify conditions that lack a pathognomonic signature to the human eye. Convolutional neural networks have been developed to detect hypertrophic cardiomyopathy from the 12-lead ECG alone, with performance maintained on external validation across diverse international cohorts and in pediatric and adolescent populations [20]. Comparable models identify electrocardiographically concealed long QT syndrome \u2014 genotype-positive individuals with a normal measured QTc \u2014 which conventional interval measurement cannot detect by definition [21].<\/p>\nThe potential relevance to this field is obvious: the principal limitation of ECG screening is not cost but interpretive accuracy, and an algorithm that improves specificity without sacrificing sensitivity would change the calculus directly. Several important caveats apply. Models trained predominantly on clinical populations may perform differently in trained athletes, whose baseline ECGs differ systematically from those of the general population, and athlete-specific validation remains limited. Performance in the demographic groups with the highest false-positive rates under conventional criteria has not been separately established. And an algorithm that flags disease without an accessible pathway to secondary evaluation reproduces the equity problem described in Section 7.5 rather than solving it. AI-ECG is best understood at present as a promising adjunct under active validation rather than an established screening tool.<\/p>\n Wearable and consumer devices.<\/strong> Smartwatches, adhesive patch monitors, and consumer single-lead and multi-lead ECG devices are now widely used by athletes, and increasingly generate cardiac data that reaches clinicians unsolicited. Their genuine strengths are duration and opportunism: a patch monitor worn for two weeks or a smartwatch worn continuously may capture a symptomatic paroxysmal arrhythmia that a resting ECG and a 24-hour Holter both miss, and this is a real diagnostic contribution in a person with intermittent palpitations.<\/p>\nTheir limitations are equally clear. Single-lead recordings cannot assess axis, chamber enlargement, repolarization across the precordium, or most of the criteria on which athlete ECG interpretation depends. Automated rhythm classification is optimized for atrial fibrillation detection in older populations and performs poorly for the arrhythmias relevant here. Signal quality during exercise \u2014 precisely when it would be most valuable \u2014 is frequently inadequate. And the false-positive burden generated by consumer devices in young, healthy, highly motivated users is substantial and largely unquantified.<\/p>\n Wearables complement rather than replace structured evaluation.<\/strong> A consumer device recording during a symptomatic episode is valuable evidence; a normal consumer recording is not clearance, and should not be treated as one by the athlete or the clinician.<\/p>\n7. Screening: What It Achieves and What It Does Not<\/h3>\nScreening is one component of prevention. This section assesses it on its own terms rather than treating it as the organizing question of the field.<\/p>\n 7.1 The rationale and its limits<\/h4>\nPreparticipation cardiovascular screening aims to identify people with unrecognized disease in time for management that reduces risk. Its effectiveness depends on a chain of conditions: the disease must be detectable before the event, the test must detect it at acceptable cost and false-positive burden, effective management must exist, and affected individuals must have access to it.<\/p>\n That chain has weak links. Resting ECG has very limited sensitivity for anomalous coronary origin, catecholaminergic polymorphic ventricular tachycardia, early or concealed arrhythmogenic cardiomyopathy, aortopathy, and significant valve disease, and by definition contributes nothing in cases that prove autopsy-negative \u2014 the largest single category. Screening addresses a subset of the problem.<\/p>\n 7.2 Comparative performance of screening components<\/h4>\nMeta-analytic estimates in athletic populations give ECG a sensitivity approaching 90\u201394% for conditions detectable by ECG<\/strong>, with specificity near 93%, against approximately 20% sensitivity for history and 9% for physical examination [18]. Evidence drawn specifically from NCAA populations has since been synthesized separately [22]. The qualifier matters: this figure describes performance against cardiomyopathies and channelopathies with electrical signatures, not against the full spectrum of causes, and should not be read as 94% sensitivity for sudden death risk overall. Contemporary guidance cites a comparable range, placing history and physical sensitivity for silent cardiac conditions at 10\u201320% and noting that adding ECG raises the sensitivity of the preparticipation evaluation to approximately 94% [1].<\/p>\nThe argument for ECG is therefore not that it performs well in absolute terms; it is that history and physical examination alone detect only a minority of relevant conditions. This is not an argument against the history and physical examination, which identifies symptomatic individuals, elicits family history, and detects Marfan stigmata, pathological murmurs, diminished femoral pulses, and hypertension \u2014 none of which an ECG reliably captures.<\/p>\n 7.3 Guideline positions<\/h4>\nEuropean guidance has long recommended ECG-inclusive screening [11,16]. North American guidance historically endorsed a standardized 14-point history and physical examination without recommending universal ECG [15].<\/p>\n That divide has narrowed substantially.<\/strong> The 2025 American Heart Association \/ American College of Cardiology scientific statement holds that inclusion of a resting 12-lead ECG is reasonable, because it improves detection of underlying cardiac conditions in asymptomatic athletes relative to history and physical examination alone. The endorsement carries three conditions: clinicians must be adequately trained in contemporary athlete-specific interpretation criteria; programs must ensure access to secondary evaluation, including the financial and logistical resources for systematic downstream assessment; and because no approach provides absolute protection, an emergency action plan must be in place wherever people train and compete [1].<\/p>\nThe unresolved questions are therefore not whether ECG may be used, but whether it should be universally implemented, how programs should be resourced to use it safely, and whether incremental benefit justifies downstream cost and harm.<\/p>\n 7.4 Health economics<\/h4>\nPublished cost-effectiveness estimates for adding ECG to preparticipation screening span a wide range, driven more by assumption choice than by data.<\/p>\n Table 3. Published economic evaluations of ECG-inclusive screening<\/strong><\/p>\n\n\n\n| Analysis<\/td>\n | Comparison<\/td>\n | Result<\/td>\n<\/tr>\n<\/thead>\n | \n\n| Wheeler et al.\u00a0(2010) [23]<\/td>\n | ECG + H&P vs.\u00a0H&P alone<\/td>\n | $42,900 per life-year saved (95% CI $21,200\u2013$71,300)<\/td>\n<\/tr>\n | \n| Wheeler et al.\u00a0(2010) [23]<\/td>\n | ECG + H&P vs.\u00a0no screening<\/td>\n | $76,100 per life-year saved ($62,400\u2013$130,000)<\/td>\n<\/tr>\n | \n| Schoenbaum et al.\u00a0(2012) [24]<\/td>\n | H&P then ECG vs.\u00a0H&P alone<\/td>\n | $68,800 per QALY<\/td>\n<\/tr>\n | \n| Schoenbaum et al.\u00a0(2012) [24]<\/td>\n | ECG alone vs.\u00a0H&P alone<\/td>\n | $37,700 per QALY<\/td>\n<\/tr>\n | \n| Halkin et al.\u00a0(2012) [25]<\/td>\n | National program, US extrapolation<\/td>\n | $10.6\u201314.4 million per life saved<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Two of the three principal analyses return figures within commonly cited US willingness-to-pay thresholds. The third, returning figures orders of magnitude higher, does so partly by loading recurring annual history and physical costs into the ECG arm \u2014 an accounting choice contested in subsequent literature [25].<\/p>\n Every one of these analyses is governed by a single assumption: the relative risk reduction conferred by detection and subsequent management. That parameter is not well established, and as discussed in Section 8 the evidence underlying it has shifted.<\/p>\n 7.5 Equity<\/h4>\nScreening programs can widen the inequities they are intended to reduce. The mechanism is the secondary evaluation, not the primary screen.<\/p>\n An abnormal screening result initiates a diagnostic cascade \u2014 echocardiography, cardiac magnetic resonance, ambulatory monitoring, genetic evaluation, subspecialty consultation \u2014 that in unassisted settings the family must fund. Uninsured and underinsured individuals face two consequences: they may exit the pathway without completing evaluation, continuing to participate with uncharacterized risk; and their absence from outcome data systematically biases estimates of disease prevalence, specificity, and cost-effectiveness in a favorable direction.<\/p>\n This is compounded by the ethnic disparity in false-positive rates. Even under contemporary criteria, false-positive findings remain more frequent among Black athletes [14], meaning that the population most likely to be referred for costly secondary evaluation overlaps with the population least likely to be able to afford it. Contemporary guidance states directly that screening programs without appropriate downstream resources have the potential to harm athletes from underrepresented racial and ethnic groups [1].<\/p>\n A screening program without a funded pathway to secondary evaluation is not a neutral intervention. It is a mechanism for identifying risk in people who cannot then act on it.<\/p>\n 7.6 Psychological consequences<\/h4>\nScreening programs are evaluated almost exclusively on detection and cost. The psychological consequences are real, are borne disproportionately by people who turn out not to have disease, and are rarely measured.<\/p>\n The false-positive interval.<\/strong> Between an abnormal screening result and its resolution, an athlete is a person who has been told their heart may be dangerously abnormal. That interval is frequently weeks and sometimes months, determined by appointment availability, insurance authorization, and imaging capacity rather than by clinical urgency. Documented consequences include anxiety, intrusive thoughts about dying during exertion, sleep disruption, and withdrawal from training during a period in which no restriction has actually been imposed. Where the athlete\u2019s identity is substantially organized around sport \u2014 as it is for many at collegiate and elite level \u2014 the threat is to selfhood as much as to health.<\/p>\nResolution is incomplete.<\/strong> Reassurance after a negative workup does not reliably return people to baseline. Residual health anxiety, continued symptom vigilance, and reduced training intensity have been described persisting after formal clearance, a pattern familiar from other screening contexts. Because false positives outnumber true positives by a large factor at any plausible operating point, this is not a marginal harm affecting a handful of people; it is the modal experience of an abnormal screen.<\/p>\nTrue positives carry their own burden.<\/strong> A diagnosis in a young person may bring restriction or modification of participation, loss of athletic identity, disrupted scholarship or professional prospects, defibrillator carriage in adolescence, and the knowledge of inherited risk extending to siblings and future children. Depression and anxiety are recognized sequelae of disqualification, and the transition out of competitive sport is itself a period of elevated psychological risk independent of the cardiac diagnosis.<\/p>\nImplications.<\/strong> Three follow directly. Time from abnormal screen to definitive resolution is a clinically meaningful quality metric, not merely an operational one, and shortening it is a genuine intervention. Communication of an abnormal result should convey the base rate \u2014 that most abnormal screens resolve without disease \u2014 rather than deferring all interpretation to the specialist. And psychological support should be planned into screening programs rather than improvised, particularly for athletes who are restricted or who transition out of competition.<\/p>\n8. Management and Sports Participation<\/h3>\n8.1 The shift from disqualification to shared decision-making<\/h4>\nHistorical practice restricted individuals with identified cardiovascular disease from competitive sport more or less categorically. That paradigm has been substantially abandoned, on both ethical and empirical grounds [1,11].<\/p>\n The empirical case rests on outcome data:<\/p>\n \n- In a prospective multinational observational study of individuals with hypertrophic cardiomyopathy \u2014 1,534 patients plus 126 genotype-positive, phenotype-negative individuals across 42 centers \u2014 those engaging in vigorous exercise, including competitive athletes, did not experience higher rates of death, resuscitated arrest, appropriate defibrillator shock, or arrhythmic syncope than moderate exercisers or sedentary participants [26].<\/li>\n
- A prospective multinational registry of athletes with implantable cardioverter-defibrillators found no deaths, resuscitated arrests, or arrhythmia-related injuries during sport over long-term follow-up [27].<\/li>\n
- Contemporary cohorts of elite athletes with genetic heart disease who returned to competition under expert supervision report low rates of breakthrough events [28].<\/li>\n<\/ul>\n
The ethical case is that the historical model rested on the premise that athletes cannot make informed decisions about their own risk \u2014 a position that is neither supported by evidence nor consistent with the standards applied elsewhere in medicine.<\/p>\n Shared decision-making does not imply equal risk across conditions.<\/strong> It is a process for incorporating an individual\u2019s values into a decision under uncertainty, not a conclusion that all diagnoses carry comparable danger or that all participation requests should be accommodated. The risk attached to genotype-positive, phenotype-negative status differs by orders of magnitude from that attached to plakophilin-2-mediated arrhythmogenic cardiomyopathy in an endurance athlete, and the framework is designed to make that difference explicit rather than to dissolve it.<\/p>\nThe 2025 AHA\/ACC statement is explicit that it does not issue disqualification recommendations, but rather clinical considerations to inform shared decision-making. Under this framework a uniform approach of restriction should not be applied to individuals with cardiomyopathy; participation is instead determined through a process incorporating accurate diagnosis, condition-specific risk stratification, guideline-directed treatment, disclosure of known and unknown risks, and the individual\u2019s own values and risk tolerance. For those under 18, parents or guardians participate directly [1].<\/p>\n 8.2 Where risk remains prohibitive<\/h4>\nShared decision-making does not mean that all participation is endorsed. Situations where risk is understood to outweigh benefit include arrhythmogenic cardiomyopathy caused by plakophilin-2 variants, particularly with endurance sport; active myocarditis or pericarditis; unrepaired anomalous origin of the left coronary artery with an interarterial course; severe symptomatic aortic stenosis; heritable thoracic aortic disease with aortic dilation; and prior aortic dissection. Participation is also generally deferred during diagnostic evaluation and until guideline-directed therapy is optimized [1].<\/p>\n 8.3 Condition-specific management<\/h4>\nManagement is disease-specific and is the mechanism by which detection produces benefit: beta-blockade in long QT syndrome and CPVT, with flecainide and sympathetic denervation in selected CPVT cases; defibrillator implantation where risk stratification indicates, though never solely to enable sport participation; catheter ablation for accessory pathways and selected ventricular arrhythmias; surgical reimplantation or unroofing for high-risk coronary anomalies; septal reduction for obstructive hypertrophic cardiomyopathy; aortic surgery at guideline thresholds; and exercise prescription modification where disease progression is exercise-associated [1].<\/p>\n Two points deserve emphasis. First, individuals who discontinue competitive sport should be counseled on the established health benefits of continued recreational physical activity \u2014 a transition, not a cessation. Second, longitudinal surveillance is required regardless of the participation decision, because phenotype evolves and the original decision may require revisiting.<\/p>\n 8.4 Return to play and longitudinal surveillance<\/h4>\nA participation decision is a point on a trajectory rather than a conclusion, and the surveillance that follows is what makes continued participation defensible.<\/p>\n Serial imaging<\/strong> at intervals determined by condition and rate of change. Genotype-positive, phenotype-negative individuals in conditions where exercise may precipitate phenotypic conversion \u2014 plakophilin-2-mediated arrhythmogenic cardiomyopathy most clearly \u2014 warrant close longitudinal surveillance, with imaging intervals individualized to phenotype, exercise exposure, and evidence of disease progression, while continuing to compete [1]. Aortic dimensions in aortopathy are followed on a schedule set by absolute diameter and rate of growth, with side-by-side comparison of images rather than reliance on prior reports, since inter-study measurement variability can exceed true annual change.<\/p>\nRepeat exercise testing<\/strong>, sport-specific and to the intensity actually encountered in competition, to confirm continued absence of provoked arrhythmia or ischemia and to verify the efficacy of pharmacological suppression where it has been prescribed.<\/p>\nAmbulatory rhythm monitoring<\/strong> to track arrhythmia burden over time, and device interrogation where a defibrillator is present, including appropriate and inappropriate therapy history.<\/p>\nStructured re-evaluation of the decision itself.<\/strong> The shared decision-making conversation should be revisited periodically rather than treated as settled \u2014 because the evidence base is changing, because the individual\u2019s own risk tolerance may change, and because phenotype progression may move a person from one risk category to another without symptoms.<\/p>\nPost-intervention return<\/strong> \u2014 after surgical coronary reimplantation, aortic repair, ablation, or device implantation \u2014 follows condition-specific intervals governed by healing, demonstrated absence of ischemia or inducible arrhythmia, and normal ventricular function, rather than by elapsed time alone.<\/p>\n9. Secondary Prevention: Emergency Response<\/h3>\nBecause no screening strategy detects all disease, and because some causes are undetectable in principle, survival in a substantial proportion of events is determined entirely by what happens in the first minutes.<\/p>\n 9.1 Determinants of survival<\/h4>\nSurvival depends on rapid recognition, immediate high-quality chest compressions, and early defibrillation, and additionally on rhythm at collapse, underlying substrate, arrest location, emergency medical services interval, airway management, post-arrest care, and neurological injury.<\/p>\n Recognition is the most common failure point in athletic settings, and the one most amenable to training.<\/strong> Bystanders are primed to interpret the collapse of a young athlete as anything other than cardiac arrest. Agonal breathing is mistaken for breathing; seizure-like activity, common in the first seconds of arrest, is mistaken for a primary neurological event. A venue with excellent defibrillator coverage can still lose several minutes to a delayed recognition decision \u2014 which is why time-to-first-compression should be measured and drilled separately from time-to-shock, since the two fail independently.<\/p>\n9.2 Emergency action plans<\/h4>\nAn adequate plan comprises a written, venue-specific document reviewed at least annually with local emergency medical services and physically accessible at each site; a designated coordinator responsible for oversight; defibrillator placement supporting a collapse-to-shock interval of three minutes or less from any point of athletic activity; documented CPR and defibrillator training among athletic trainers, coaching staff, and strength staff; rehearsal drills with time-to-first-compression and time-to-shock recorded; and a coordinated transport plan to a designated receiving facility [1].<\/p>\n Where such plans have been prospectively studied in high school settings, survival to hospital discharge has substantially exceeded rates observed for out-of-hospital cardiac arrest generally [29] \u2014 a difference attributable to witnessed collapse, trained responders, and immediate defibrillator availability rather than to any characteristic of the individuals.<\/p>\n A final observation on policy. Sudden cardiac arrest and death will continue to occur irrespective of screening strategy and participation decisions, and their occurrence should not be interpreted as evidence that a shared decision-making approach has failed. Sound policy is not well made in the immediate aftermath of an individual event.<\/p>\n 10. Family Evaluation<\/h3>\nA diagnosis of inherited heart disease is a diagnosis about a family. Where a proband is identified \u2014 living or deceased \u2014 first-degree relatives warrant clinical evaluation, and cascade genetic testing where a pathogenic variant has been identified [1].<\/p>\n This applies with particular force after an unexplained death. Postmortem specimen retention adequate for genetic analysis is not universal practice among medical examiners, and its absence forecloses the family\u2019s diagnostic pathway permanently. Where molecular autopsy is combined with clinical evaluation of surviving relatives, a clinically relevant diagnosis is established in a substantially higher proportion of families than by either approach alone [12].<\/p>\n Cascade evaluation identifies relatives who carry risk before it manifests \u2014 the only circumstance in this field where prevention operates on a clearly identified population rather than an unselected one, and correspondingly the setting where the yield of evaluation is highest.<\/p>\n 11. Knowledge Gaps<\/h3>\nSeveral questions central to this field remain unresolved, and are unlikely to be settled by the study designs typically proposed.<\/p>\n Whether screening reduces mortality cannot be established by randomized trial.<\/strong> At an incidence near 1 per 63,682 athlete-years [4], demonstrating a 50% relative reduction with conventional power would require on the order of ten million athlete-years of observation. The Italian regional experience and the contradictory Israeli national experience are both observational [30,31], both confounded by secular trend and ascertainment change, and both are why the question remains open after four decades. This is a structural feature of studying a rare outcome, not a deficiency of effort.<\/p>\nThe real-world false-positive rate is unknown.<\/strong> Published rates derive from expert interpretation. The rate achieved by clinicians who would actually staff population screening has not been established at scale, and it is the parameter that determines whether ECG-inclusive screening is feasible outside academic centers.<\/p>\nThe magnitude of benefit from detection is uncertain and has probably narrowed.<\/strong> Legacy economic models assume that detection leads to restriction and that restriction prevents death. The second link has weakened considerably. Benefit now plausibly derives more from disease-specific treatment, family cascade screening, and targeted emergency preparedness than from removal from sport.<\/p>\nThe true cost and completion rate of the diagnostic cascade are not established<\/strong>, because existing data derive from settings in which financially constrained individuals exit the pathway before completion.<\/p>\nThe mechanism of the observed decline in incidence is unknown<\/strong>, and attributing it to screening is not supported by the data.<\/p>\nSudden death in non-athletic young people is comparatively uncharacterized.<\/strong> The population is larger, the ascertainment poorer, and the preventive infrastructure absent.<\/p>\n12. Summary<\/h3>\nSudden cardiac death in the young is rare, concentrated, and heterogeneous in cause. Risk varies several-fold by sex, race, and sport, with Division I male basketball players the highest-risk studied group at roughly 1 in 2,000 over a four-year career. The etiologic picture is no longer dominated by hypertrophic cardiomyopathy: autopsy-negative sudden unexplained death is the most common single finding, and a meaningful fraction of these cases prove on molecular autopsy to be inherited arrhythmia syndromes.<\/p>\n Exercise acts as a trigger through catecholaminergic surge, demand ischemia, mechanical stress, electrolyte shift, and abrupt autonomic transition \u2014 and in at least one condition, plakophilin-2-mediated arrhythmogenic cardiomyopathy, as a driver of disease progression rather than merely a trigger.<\/p>\n Distinguishing physiological cardiac adaptation from disease is the central diagnostic challenge, and criteria for doing so on the ECG have improved markedly, reducing false-positive rates from roughly 40% to under 7% in Black athletes across fifteen years of refinement. Contemporary guidance on both sides of the Atlantic now regards ECG-inclusive screening as reasonable, conditioned on trained interpretation, assured access to secondary evaluation, and emergency preparedness.<\/p>\n Management has moved from categorical disqualification to shared decision-making, supported by outcome data showing lower risk from continued participation than was historically assumed. Detection produces benefit principally through disease-specific treatment, family cascade screening, and targeted preparedness rather than through removal from sport.<\/p>\n No screening strategy prevents all events. Emergency action planning, rapid recognition, immediate compressions, and early defibrillation remain the last and most reliable line of prevention, and in well-prepared settings save a majority of those who arrest.<\/p>\n References<\/h3>\n\n- Kim JH, Baggish AL, Levine BD, et al. Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol<\/em>. 2025;85(10):1059-1108. doi:10.1016\/j.jacc.2024.12.025<\/li>\n
- Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation<\/em>. 2009;119(8):1085-1092. doi:10.1161\/CIRCULATIONAHA.108.804617<\/li>\n
- Harmon KG, Asif IM, Maleszewski JJ, et al. Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review. Circulation<\/em>. 2015;132(1):10-19. doi:10.1161\/CIRCULATIONAHA.115.015431<\/li>\n
- Petek BJ, Churchill TW, Moulson N, et al. Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study. Circulation<\/em>. 2024;149(2):80-90. doi:10.1161\/CIRCULATIONAHA.123.065908<\/li>\n
- Moulson N, Petek BJ, Ackerman MJ, et al. Rationale and Design of the ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) Study. J Am Heart Assoc<\/em>. 2023;12(11):e029052. doi:10.1161\/JAHA.122.029052<\/li>\n
- Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete’s heart in women. Echocardiographic characterization of highly trained elite female athletes. JAMA<\/em>. 1996;276(3):211-215. doi:10.1001\/jama.276.3.211<\/li>\n
- Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med<\/em>. 2000;343(19):1355-1361. doi:10.1056\/NEJM200011093431902<\/li>\n
- Franklin BA, Thompson PD, Al-Zaiti SS, et al. Exercise-Related Acute Cardiovascular Events and Potential Deleterious Adaptations Following Long-Term Exercise Training: Placing the Risks Into Perspective\u2014An Update: A Scientific Statement From the American Heart Association. Circulation<\/em>. 2020;141(13):e705-e736. doi:10.1161\/CIR.0000000000000749<\/li>\n
- Sejersted OM, Sj\u00f8gaard G. Dynamics and consequences of potassium shifts in skeletal muscle and heart during exercise. Physiol Rev<\/em>. 2000;80(4):1411-1481. doi:10.1152\/physrev.2000.80.4.1411<\/li>\n
- James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia\/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol<\/em>. 2013;62(14):1290-1297. doi:10.1016\/j.jacc.2013.06.033<\/li>\n
- Sharma S, Pelliccia A, Gati S. The ‘Ten Commandments’ for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease. Eur Heart J<\/em>. 2021;42(1):6-7. doi:10.1093\/eurheartj\/ehaa735<\/li>\n
- Lahrouchi N, Raju H, Lodder EM, et al. Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. J Am Coll Cardiol<\/em>. 2017;69(17):2134-2145. doi:10.1016\/j.jacc.2017.02.046<\/li>\n
- Drezner JA, Sharma S, Baggish A, et al. International criteria for electrocardiographic interpretation in athletes: Consensus statement. Br J Sports Med<\/em>. 2017;51(9):704-731. doi:10.1136\/bjsports-2016-097331<\/li>\n
- Sheikh N, Papadakis M, Ghani S, et al. Comparison of electrocardiographic criteria for the detection of cardiac abnormalities in elite black and white athletes. Circulation<\/em>. 2014;129(16):1637-1649. doi:10.1161\/CIRCULATIONAHA.113.006179<\/li>\n
- Maron BJ, Levine BD, Washington RL, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation<\/em>. 2015;132(22):e267-e272. doi:10.1161\/CIR.0000000000000238<\/li>\n
- Corrado D, Pelliccia A, Heidbuchel H, et al. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J<\/em>. 2010;31(2):243-259. doi:10.1093\/eurheartj\/ehp473<\/li>\n
- Drezner JA, Ackerman MJ, Anderson J, et al. Electrocardiographic interpretation in athletes: the ‘Seattle criteria’. Br J Sports Med<\/em>. 2013;47(3):122-124. doi:10.1136\/bjsports-2012-092067<\/li>\n
- Harmon KG, Zigman M, Drezner JA. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: a systematic review\/meta-analysis. J Electrocardiol<\/em>. 2015;48(3):329-338. doi:10.1016\/j.jelectrocard.2015.02.001<\/li>\n
- Malhotra A, Dhutia H, Finocchiaro G, et al. Outcomes of Cardiac Screening in Adolescent Soccer Players. N Engl J Med<\/em>. 2018;379(6):524-534. doi:10.1056\/NEJMoa1714719<\/li>\n
- Siontis KC, Wieczorek MA, Maanja M, et al. Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study. Eur Heart J Digit Health<\/em>. 2024;5(4):416-426. Published 2024 Apr 15. doi:10.1093\/ehjdh\/ztae029<\/li>\n
- Bos JM, Attia ZI, Albert DE, Noseworthy PA, Friedman PA, Ackerman MJ. Use of Artificial Intelligence and Deep Neural Networks in Evaluation of Patients With Electrocardiographically Concealed Long QT Syndrome From the Surface 12-Lead Electrocardiogram. JAMA Cardiol<\/em>. 2021;6(5):532-538. doi:10.1001\/jamacardio.2020.7422<\/li>\n
- Conway JJ, Bennett D, Asif IM, Teramoto M, Toresdahl BG. Pre-participation cardiovascular screening among NCAA athletes: a systematic review and meta-analysis of 27 891 athletes. Br J Sports Med<\/em>. 2026;60(5):379-387. Published 2026 Mar 12. doi:10.1136\/bjsports-2025-110791<\/li>\n
- Wheeler MT, Heidenreich PA, Froelicher VF, Hlatky MA, Ashley EA. Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes. Ann Intern Med<\/em>. 2010;152(5):276-286. doi:10.7326\/0003-4819-152-5-201003020-00005<\/li>\n
- Schoenbaum M, Denchev P, Vitiello B, Kaltman JR. Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics<\/em>. 2012;130(2):e380-e389. doi:10.1542\/peds.2011-3241<\/li>\n
- Halkin A, Steinvil A, Rosso R, Adler A, Rozovski U, Viskin S. Preventing sudden death of athletes with electrocardiographic screening: what is the absolute benefit and how much will it cost?. J Am Coll Cardiol<\/em>. 2012;60(22):2271-2276. doi:10.1016\/j.jacc.2012.09.003<\/li>\n
- Lampert R, Ackerman MJ, Marino BS, et al. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol<\/em>. 2023;8(6):595-605. doi:10.1001\/jamacardio.2023.1042<\/li>\n
- Lampert R, Olshansky B, Heidbuchel H, et al. Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Long-Term Results of a Prospective Multinational Registry. Circulation<\/em>. 2017;135(23):2310-2312. doi:10.1161\/CIRCULATIONAHA.117.027828<\/li>\n
- Martinez KA, Bos JM, Baggish AL, et al. Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death. J Am Coll Cardiol<\/em>. 2023;82(8):661-670. doi:10.1016\/j.jacc.2023.05.059<\/li>\n
- Drezner JA, Toresdahl BG, Rao AL, Huszti E, Harmon KG. Outcomes from sudden cardiac arrest in US high schools: a 2-year prospective study from the National Registry for AED Use in Sports. Br J Sports Med<\/em>. 2013;47(18):1179-1183. doi:10.1136\/bjsports-2013-092786<\/li>\n
- Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA<\/em>. 2006;296(13):1593-1601. doi:10.1001\/jama.296.13.1593<\/li>\n
- Steinvil A, Chundadze T, Zeltser D, et al. Mandatory electrocardiographic screening of athletes to reduce their risk for sudden death proven fact or wishful thinking?. J Am Coll Cardiol<\/em>. 2011;57(11):1291-1296. doi:10.1016\/j.jacc.2010.10.037<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"
Conozca las causas, los factores de riesgo y la detecci\u00f3n de la muerte s\u00fabita card\u00edaca en atletas j\u00f3venes. Descubra c\u00f3mo el uso r\u00e1pido de un DEA y los planes de emergencia salvan vidas.<\/p>","protected":false},"author":16,"featured_media":12332,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[228,218,225,226],"tags":[],"class_list":["post-12324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-athletes-and-heart-risk","category-exercise-athletes-and-aging","category-risk-genetics-special-populations","category-special-populations"],"acf":[],"yoast_head":"\n How not to die young - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/es\/como-no-morir-joven\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How not to die young - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Learn about the causes, risk factors, and screening of sudden cardiac death in young athletes. Discover how rapid AED use and emergency plans save lives.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/es\/como-no-morir-joven\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-02T17:49:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T18:12:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/08\/post-image-88.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"41 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"How not to die young\",\"datePublished\":\"2026-08-02T17:49:40+00:00\",\"dateModified\":\"2026-08-12T18:12:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/\"},\"wordCount\":9067,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/post-image-88.jpg\",\"articleSection\":[\"Athletes and Heart Risk\",\"Exercise, Athletes and Aging\",\"Risk, Genetics and Special Populations\",\"Special Populations\"],\"inLanguage\":\"es-AR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/\",\"name\":\"How not to die young - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/post-image-88.jpg\",\"datePublished\":\"2026-08-02T17:49:40+00:00\",\"dateModified\":\"2026-08-12T18:12:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/#breadcrumb\"},\"inLanguage\":\"es-AR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-AR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/post-image-88.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/post-image-88.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/how-not-to-die-young\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How not to die young\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-AR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-AR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"C\u00f3mo no morir joven: la principal plataforma de educaci\u00f3n sobre la salud card\u00edaca","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/es\/como-no-morir-joven\/","og_locale":"es_ES","og_type":"article","og_title":"How not to die young - The Premiere Heart Health Education Platform","og_description":"Learn about the causes, risk factors, and screening of sudden cardiac death in young athletes. Discover how rapid AED use and emergency plans save lives.","og_url":"https:\/\/www.curingheartdisease.com\/es\/como-no-morir-joven\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2026-08-02T17:49:40+00:00","article_modified_time":"2026-08-12T18:12:26+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/08\/post-image-88.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"Escrito por":"Peter Megdal PhD","Tiempo de lectura":"41 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"How not to die young","datePublished":"2026-08-02T17:49:40+00:00","dateModified":"2026-08-12T18:12:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/"},"wordCount":9067,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/08\/post-image-88.jpg","articleSection":["Athletes and Heart Risk","Exercise, Athletes and Aging","Risk, Genetics and Special Populations","Special Populations"],"inLanguage":"es-AR"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/","url":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/","name":"C\u00f3mo no morir joven: la principal plataforma de educaci\u00f3n sobre la salud card\u00edaca","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/08\/post-image-88.jpg","datePublished":"2026-08-02T17:49:40+00:00","dateModified":"2026-08-12T18:12:26+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/#breadcrumb"},"inLanguage":"es-AR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/"]}]},{"@type":"ImageObject","inLanguage":"es-AR","@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/08\/post-image-88.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/08\/post-image-88.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/how-not-to-die-young\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"How not to die young"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"La principal plataforma de educaci\u00f3n sobre la salud card\u00edaca","description":"Poner a disposici\u00f3n del p\u00fablico la informaci\u00f3n m\u00e1s avanzada sobre c\u00f3mo revertir la enfermedad card\u00edaca. Esta es una organizaci\u00f3n basada en la evidencia que utiliza la mejor ciencia disponible, incluyendo dieta, ejercicio, medicamentos y otros recursos para combatir de la mejor manera esta enfermedad.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-AR"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"Curing Heart Disease, LLC","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"es-AR","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"Curing Heart Disease, LLC es una organizaci\u00f3n independiente de educaci\u00f3n sobre salud cardiovascular que publica art\u00edculos, videos, p\u00f3dcasts y herramientas educativas basados en evidencia cient\u00edfica sobre la prevenci\u00f3n de enfermedades cardiovasculares, la ciencia de los l\u00edpidos, la nutrici\u00f3n, el ejercicio y temas de salud relacionados.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD es investigador en nutrici\u00f3n, educador en salud cardiovascular, autor de publicaciones cient\u00edficas y ciclista de competencia desde hace mucho tiempo. Obtuvo un doctorado en nutrici\u00f3n de la Universidad de Massachusetts y difunde informaci\u00f3n educativa sobre salud cardiovascular basada en la evidencia a trav\u00e9s de Curing Heart Disease.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts\/12324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/comments?post=12324"}],"version-history":[{"count":9,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts\/12324\/revisions"}],"predecessor-version":[{"id":12942,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts\/12324\/revisions\/12942"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/media\/12332"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/media?parent=12324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/categories?post=12324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/tags?post=12324"}],"curies":[{"name":"\u00a1Bien jugado!","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | |